Detection method of OXA type carbapenemase drug-resistant gene
Through enzymatic recombinant isothermal amplification technology combined with specific primers and fluorescent probes, the existing OXA gene detection problem is solved, and the rapid and high specificity OXA gene detection is achieved, which is suitable for on-site applications in room temperature.
Patent Information
- Application Number
- CN202411503537.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2024-12-06
AI Technical Summary
The existing OXA gene detection methods are time-consuming, cumbersome, low sensitivity, and are not suitable for on-site testing at room temperature, making it difficult to quickly and accurately detect carbapenem antibiotic-resistant bacteria.
The OXA gene detection was completed within 15-20 minutes by enzymatic recombinant isothermal amplification technology (ERA) combined with specific primers and fluorescent probes through isothermal amplification method at 37°C to 42°C, and specific primers such as SEQ were used. ID NO:3 and SEQ ID NO:5, and probes such as SEQ ID NO:6, enable fast and sensitive detection.
The rapid detection of OXA gene is achieved, with a sensitivity of 0.01ng/μL, high specificity, and no cross-reactions. It is correct with other carbapenemase subtype genes. It is suitable for on-site detection at room temperature, simplifying the operation process and reducing the detection. Time and cost.
Smart Images

Figure BDA0005103195780000071 
Figure BDA0005103195780000102 
Figure HDA0005103195790000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular, relates to a specific primer pair, a probe, a detection kit and a detection method for rapidly detecting a carbapenem antibiotic resistance gene OXA based on ERA technology. Background Art
[0002] Bacterial resistance has become a major challenge in the field of global public health, among which the infection caused by carbapenem-resistant Enterobacteriaceae (CRE) is the most serious. Carbapenem antibiotics have become one of the most important antibacterial drugs for the treatment of serious bacterial infections due to their broad antibacterial spectrum and strong antibacterial activity. However, with the excessive use of carbapenem antibiotics in clinical practice in recent years, many bacteria can hydrolyze carbapenem antibiotics by producing carbapenemases and inactivate them, leading to the production of carbapenem-resistant Enterobacteriaceae (CRE), which is becoming a widespread epidemic worldwide.
[0003] Based on the similarity of amino acid sequences, carbapenemases are divided into two superfamilies: A and D classes with serine as the active center, and B class whose active center requires the assistance of metal ions. Oxacillinase OAX is a class D carbapenemases, and bacteria that produce this type of enzyme are resistant to almost all β-lactam antibiotics. The enzyme encoding gene is usually present on mobile genetic factors such as plasmids, has a strong transfer ability, and can be transmitted within or between bacteria by conjugation, thereby increasing the speed and scope of the spread of drug resistance.
[0004] At present, the detection of OXA mainly includes phenotypic screening, genotypic detection and immunochromatography technology. Phenotypic detection methods include Carba NP test, mCIM and eCIM, carbapenemase inhibitor enhancement test and time-of-flight mass spectrometry technology. These methods have the disadvantages of being time-consuming and cumbersome to operate. Genotypic detection methods include enzyme immunochromatography technology and molecular detection technology. Traditional gene identification methods are PCR and DNA sequencing. Among them, the traditional PCR method has a long detection cycle, usually 3-4 hours. The Sanger DNA sequencing method has high requirements for primer specificity, is expensive, and has complex data analysis in the later stage, which is not suitable for clinical promotion.
[0005] Therefore, there is an urgent need to develop a detection method for the OXA gene that is simple to operate, time-saving, highly sensitive, and specific and suitable for on-site detection at room temperature. Summary of the invention
[0006] The object of the present invention is to provide a method for detecting OXA gene which is simple to operate, short in time, highly sensitive, highly specific and suitable for on-site detection at room temperature.
[0007] In a first aspect of the present invention, a non-diagnostic and non-therapeutic OXA gene amplification method is provided, the amplification method comprising the steps of: performing amplification in a reaction system, the reaction system containing a specific primer pair for amplifying the OXA gene, the primer pair comprising: a sequence as shown in SEQ ID NO: 3, and a sequence as shown in SEQ ID NO: 5.
[0008] In another preferred embodiment, the minimum detection concentration of OXA in the method is 0.005-0.015 ng / μL.
[0009] In another preferred embodiment, the minimum detection concentration of OXA in the method is 0.01 ng / μL.
[0010] In another preferred embodiment, the reaction system further comprises a probe, and the probe comprises a sequence as shown in SEQ ID NO:6.
[0011] In another preferred embodiment, the probe is labeled with a fluorescent group and a quencher group.
[0012] In another preferred embodiment, the 5' end of the probe is labeled with a fluorescent gene FAM, and the 3' end is labeled with a quenching group BHQ.
[0013] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 5 or its complementary chain.
[0014] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 1 or its complementary chain, and a sequence as shown in SEQ ID NO: 4 or its complementary chain.
[0015] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 3 or its complementary chain, and a sequence as shown in SEQ ID NO: 4 or its complementary chain.
[0016] In another preferred embodiment, the method further comprises: performing an amplification reaction in another positive (control) reaction system or a negative (control) reaction system.
[0017] In another preferred embodiment, the positive reaction system comprises genomic DNA of a drug-resistant Klebsiella pneumoniae strain expressing OXA.
[0018] In another preferred embodiment, the reaction system further comprises amplification elements such as DNA polymerase, single-stranded binding protein, endonuclease IV, recombinase and auxiliary protein.
[0019] In another preferred embodiment, the method further comprises the step of detecting the fluorescent signal emitted by the specific probe during or after the amplification reaction.
[0020] In another preferred embodiment, the method is enzymatic isothermal amplification (ERA).
[0021] In another preferred embodiment, the reaction reagents of the ERA further include: one or more of a universal solvent for the ERA reaction system, an activator, a fluorescent amplification reagent, and ddH2O.
[0022] In another preferred embodiment, the reaction temperature of the ERA isothermal amplification is 36°C to 42°C, preferably 37°C to 39°C.
[0023] In another preferred embodiment, the reaction time of the ERA isothermal amplification is 15-60 minutes, preferably 15-20 minutes.
[0024] In a second aspect of the present invention, a non-diagnostic detection method for OXA gene is provided, the method comprising the steps of:
[0025] (a) amplifying the sample to be tested using the method described in the first aspect of the present invention; and
[0026] (b) Perform signal detection.
[0027] In another preferred embodiment, the method further comprises processing the sample to be tested to obtain genomic DNA, and then amplifying the target DNA by the method described in the first aspect of the present invention.
[0028] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.
[0029] In another preferred embodiment, the method further comprises setting up one or more control groups.
[0030] In another preferred example, the control group includes a negative control group and a positive control group.
[0031] In another preferred embodiment, the positive control group includes OXA-producing Klebsiella pneumoniae resistant strains.
[0032] In another preferred embodiment, the method includes qualitative detection and quantitative detection.
[0033] In another preferred embodiment, the minimum detection concentration of OXA in the method is 0.005-0.015 ng / μL.
[0034] In another preferred embodiment, the minimum detection concentration of the method is 0.01 ng / μL.
[0035] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
[0036] In another preferred example, the detection includes fluorescence signal detection.
[0037] In another preferred embodiment, the fluorescence detection includes using a fluorescence quantitative PCR instrument or using a handheld fluorescence detector for real-time detection.
[0038] In a third aspect of the present invention, a detection kit for rapid detection of OXA gene is provided, the detection kit comprising:
[0039] a container, and a primer pair and a probe specific for the OXA gene in the container,
[0040] Wherein, the specific primer pair includes the sequence shown as SEQ ID NO:3 and the sequence shown as SEQ ID NO:5; and the probe includes the sequence shown as SEQ ID NO:6.
[0041] In another preferred embodiment, the detection kit further comprises elements such as DNA polymerase, single-strand binding protein, endonuclease IV, recombinase and auxiliary protein.
[0042] In another preferred example, the detection kit further comprises a sample processing reagent, and the sample processing reagent comprises a cell lysis solution, a nucleic acid extraction solution, a washing solution and the like.
[0043] In another preferred example, the detection kit further includes an ERA reaction reagent, and the ERA reaction reagent includes one or more of a universal dissolving agent, an activating agent, a fluorescent amplification reagent, and ddH2O.
[0044] In another preferred embodiment, the detection kit further comprises an OXA positive control and an OXA negative control.
[0045] In another preferred embodiment, the detection kit further comprises an instruction manual, wherein the instruction manual is used to guide the detection of the OXA gene.
[0046] In a fourth aspect of the present invention, there is provided a use of the detection kit as described in the third aspect, for non-diagnostic and non-therapeutic detection of whether a sample to be tested contains OXA-type carbapenemase-resistant bacteria.
[0047] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.
[0048] In another preferred embodiment, the kit is used to identify whether the sample to be tested contains OXA-type carbapenemase-resistant bacteria. By detecting the OXA gene content C0 of the sample to be tested and the OXA gene content C1 in the negative control sample, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain OXA-type carbapenemase-resistant bacteria.
[0049] In another preferred embodiment, the kit is also used to evaluate the antibacterial effect of drugs against OXA-type carbapenemase-resistant bacteria. The OXA gene content Z0 in the sample after the drug treatment of OXA-type carbapenemase-resistant bacteria and the OXA gene content Z1 in the sample without the above-mentioned drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting OXA-type carbapenemase-resistant bacteria.
[0050] In a fifth aspect of the present invention, a specific primer pair for amplifying the OXA gene is provided, the primer pair comprising a sequence as shown in SEQ ID NO:3 and a sequence as shown in SEQ ID NO:5.
[0051] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 5 or its complementary chain.
[0052] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 1 or its complementary chain, and a sequence as shown in SEQ ID NO: 4 or its complementary chain.
[0053] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 3 or its complementary chain, and a sequence as shown in SEQ ID NO: 4 or its complementary chain.
[0054] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 The amplification test results of 6 primer pairs of OXA gene in carbapenem-resistant Klebsiella pneumoniae by ERA method are shown. The primer pair information is shown in Table 2.
[0056] Figure 2 Shown are the test results of the optimal primer pair for detecting different concentrations of Klebsiella pneumoniae genomic DNA.
[0057] Figure 3 Shown are the test results of the optimal primer pair for detecting different concentrations of Klebsiella pneumoniae genomic DNA in human feces.
[0058] Figure 4 The results of cross-reactivity specificity testing of the optimal primer pairs on different genomes are shown. DETAILED DESCRIPTION
[0059] After extensive and in-depth research and a large number of screenings, the inventors have developed a method for rapid detection of the OXA gene based on enzymatic recombinant isothermal amplification (ERA). Experiments have shown that the method has a sensitivity of 0.01 ng / μL, high detection specificity, and no cross-reaction with NDM, VIM, IMP, and KPC genomic DNA, and can be used for rapid screening and detection of OXA-producing carbapenem antibiotic-resistant bacteria. The present invention was completed on this basis.
[0060] the term
[0061] In order to make the present invention more easily understood, some technical and scientific terms are specifically defined below. Unless otherwise specifically defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.
[0062] As used herein, the terms "comprise", "include", and "contain" are used interchangeably and include not only closed definitions, but also semi-closed and open definitions. In other words, the terms include "consisting of", "consisting essentially of".
[0063] Primers and probes
[0064] As used herein, the term "OXA gene specific primers" refers to primers (pairs) that amplify products having complementary strand sequences of the OXA gene. Preferred primer sequences include a primer pair consisting of SEQ ID NO:3 and SEQ ID NO:5.
[0065] In the amplification method of the present invention, in addition to the primers, the reaction system may also include one or more probes, such as OXA fluorescent probe, for detecting the amplification effect of the OXA gene. The probe has a FAM fluorescent group and a BHQ quenching group, and has a blocking group at the 3'-end to block the polymerase extension of the probe. A preferred detection probe of the present invention has a nucleotide sequence as shown in SEQ ID NO:6.
[0066] In the present invention, many primer sequences were designed, and six primer pairs were formed by combining two of them. After a large number of experimental screenings, the combination of SEQ ID NO: 3 and SEQ ID NO: 5 with high specificity and high sensitivity was finally selected, and its sensitivity could reach 2.2017 copies / μL.
[0067] ERA
[0068] Enzymatic Recombinase Amplification (ERA) is an isothermal amplification technology developed by Suzhou Xinda Gene Technology Co., Ltd. in China. Through genetic engineering, the multi-enzyme system of recombinase, exonuclease, polymerase, etc. is modified to establish a special amplification reaction system. At room temperature, the specific segment of trace DNA / RNA can be amplified billions of times within a few minutes. It has the advantages of being fast and simple, easy to operate, and having reliable results.
[0069] The present invention uses ERA to detect OXA gene, which includes, in addition to specific primers and probes, universal reaction reagents of ERA, including one or more of universal solvent, activator, fluorescent amplification reagent, and ddH2O. When other methods are used to detect OXA, the specific primers and probes of the present invention can also be used to cooperate with reaction reagents applicable to other methods to perform OXA detection.
[0070] OXA
[0071] Oxacillinase OAX belongs to the class D carbapenemases, and bacteria producing this type of enzyme are resistant to almost all β-lactam antibiotics. Carbapenemases also include OXA type, NDM type, KPC type, and VIM type.
[0072] In the present invention, "carbapenem antibiotic-resistant bacteria" and "carbapenemase-resistant bacteria" are used interchangeably to refer to bacteria that express carbapenemase and are resistant to carbapenem antibiotics.
[0073] The OXA-producing Klebsiella pneumoniae resistant strains involved in the present invention were donated by the First Affiliated Hospital of Nanchang University. The fecal samples of healthy volunteers were obtained from the Hospital of Shanghai Institute of Biomedicine and Pharmacology.
[0074] The present invention is designed for the OXA gene and includes 3 upstream primers (SEQ ID NOs: 1-3), 2 downstream primers (SEQ ID NOs: 4-5), and 1 probe (SEQ ID NO: 6), as shown in Table 1.
[0075] Table 1 Primer and probe sequences
[0076]
[0077] (FAM-dT)(THF)(BHQ1-dT) indicates that the probe consists of an oligonucleotide backbone consisting of a flanking FAM-dT fluorophore, a deoxynucleotide analog (tetrahydrofuran [THF] residue), and a BHQ1-dT quencher.
[0078] (C3-SPACER) here stands for: 3'-blocking group to block polymerase extension of the probe.
[0079] Detection Methods
[0080] The present invention provides a method for detecting OXA gene, comprising amplifying a sample to be tested using the specific primers of the present invention; and
[0081] During or after the amplification reaction, the amplified product of the OXA gene is detected, for example, by detecting the fluorescent signal emitted by the specific probe.
[0082] The method may also optionally include setting up one or more control groups, such as an OXA positive control group, an OXA negative control group, and the like.
[0083] Preferably, the OXA positive control group is genomic DNA of resistant Klebsiella pneumoniae expressing OXA.
[0084] Preferably, the OXA negative control group is PCR water.
[0085] In the present invention, the detection method can be a conventional PCR method, or a different method such as real-time fluorescence PCR. Preferably, the present invention uses the ERA method.
[0086] Typically, the ERA method of the present invention comprises the following steps:
[0087] S1. DNA from stool samples was extracted using thermal lysis method as a template;
[0088] S2. Amplifying DNA in an ERA reaction system comprising specific primers and specific probes of the present invention;
[0089] S3. Signal detection is performed through the fluorescent signal carried by the specific probe.
[0090] Among them, the ERA reaction system also includes other ERA reaction reagents, such as universal solvent, activator, fluorescence amplification reagent, ddH2O, etc.
[0091] Detection Kits
[0092] The present invention also provides an OXA gene detection kit, which contains a specific detection reagent and can more accurately identify whether the sample to be tested contains carbapenemase-resistant bacteria, especially OXA-type carbapenemase-resistant bacteria. By detecting the OXA gene content C0 of the sample to be tested and the OXA gene content C1 in the negative control, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain OXA-type carbapenemase-resistant bacteria.
[0093] Preferably, the detection reagents of the detection kit of the present invention include specific primers, specific probes, reagents for preparing the ERA reaction system, and the like.
[0094] The detection reagent of the present invention further comprises a container and an instruction manual, wherein the container is used to contain the detection reagent, and the instruction manual is used to guide the use of the detection reagent.
[0095] Based on this kit, the present invention can further provide the antibacterial effect of the drug against OXA-type carbapenemase-resistant bacteria. After the drug treatment of OXA-type carbapenemase-resistant bacteria, the OXA gene content Z0 in the sample and the OXA gene content Z1 in the sample without the above drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting OXA-type carbapenemase-resistant bacteria.
[0096] Compared with the prior art, the advantages of the present invention are as follows:
[0097] 1. The technical solution provided by the present invention takes the OXA gene as the detection target, relies on enzymatic amplification reaction, uses a specific primer and probe combination, and completes the detection within 20 minutes through constant temperature amplification technology. It does not require a complicated sample DNA pretreatment process or thermal deformation of the template, and is easy to operate and time-saving.
[0098] 2. The reaction conditions of the technical solution of the present invention are 37-42°C, and the temperature control does not need to be particularly strict, nor does it need to set multiple parameters, and the energy consumption is low. Therefore, it is particularly suitable for on-site operation.
[0099] 3. The technical solution of the present invention uses fluorescence numerical interpretation results, eliminating the process of electrophoresis verification of PCR products and avoiding aerosol contamination.
[0100] 4. The specific primer pair and probe of the OXA gene of the present invention have extremely high sensitivity, with a minimum detection concentration of about 0.01 ng / μL. They also have high specificity and have no cross-reaction with other subtype genes of carbapenemase.
[0101] 5. The OXA gene detection kit of the present invention can be used as a reagent for detecting OXA genes in clinical specimens (excreta, etc.) or clinical isolates, and can be used for scientific research and clinical applications.
[0102] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0103] Example 1. Screening for the optimal primer pair for detecting OXA gene specific amplification
[0104] Table 2 Primer pairs for detecting OXA gene specific amplification
[0105] Primer pairs 1 SEQ ID NO:1+SEQ ID NO:4 2 SEQ ID NO:1+SEQ ID NO:5 3 SEQ ID NO:2+SEQ ID NO:4 4 SEQ ID NO:2+SEQ ID NO:5 5 SEQ ID NO:3+SEQ ID NO:4 6 SEQ ID NO:3+SEQ ID NO:5
[0106] The upstream and downstream primers described in Table 1 were paired in pairs to form 6 primer pairs, as shown in Table 2. The OXA-producing Klebsiella pneumoniae resistant strains were used as the detection object to detect the effects of different primer pairs in the specific amplification of the OXA gene, and SEQ ID NO: 6 was the probe sequence.
[0107] DNA sample preparation: The template DNA is the genomic DNA extracted from the above strains after culture. Specifically, the strains were cultured in brain heart infusion broth (BHI) medium containing ampicillin (50 μg / mL) at 37°C according to the standard protocol, and then Plasmid DNA Mini Kit I (D6942-01) was used to extract genomic DNA according to the instructions. The template DNA was diluted 10 times in a row, and the working concentration was 10.0 ng / μl.
[0108] ERA isothermal amplification: Amplification was performed using the ERA isothermal amplification reaction system. The 50ul amplification reaction system was constructed as follows:
[0109]
[0110] The amplification temperature was 37°C and the reaction lasted for 20 min.
[0111] Fluorescence detection: During the reaction, the GS8 fluorescence thermostatic amplification instrument was used to detect the change in fluorescence value, and the fluorescence was read every 30 seconds until the reaction was completed. On the fluorescence detector, the positive group showed an "S" curve with an exponential amplification trend; the negative group showed a flat horizontal straight line with no amplification trend, and the fluorescence signal was <200; the TT (time threshold) value was 4 to 8 minutes; the fluorescence signal value range of the product was: 6000-13000. Parallel experiments were performed with different primer pairs to detect the fluorescence results.
[0112] The test results showed that after a large number of screenings, the following combinations were selected from the six primer pair combinations: SEQ ID NO: 1 (F) + SEQ ID NO: 4 (R); SEQ ID NO: 3 (F) + SEQ ID NO: 4 (R) and SEQ ID NO: 3 (F) + SEQ ID NO: 5 (R), which had good sensitivity and specificity. Among them, the best primer pair was SEQ ID NO: 3 (F) + SEQ ID NO: 5 (R) ( Figure 1 ).
[0113] Example 2. Minimum detection concentration of OXA gene
[0114] Select the following optimal primer pairs and probe sequences:
[0115] SEQ ID NO:3(F):5'-AAACTGGATACTCGACTAGAATCGAACCTAA-3'
[0116] SEQ ID NO:5(R):5'-CCCAGGCGACTTGGCCTTGCTGTCCTGAT-3'
[0117] SEQ ID NO:6(probe):5'-TGGTGGGTCGGTYGGGTTGAACTTGATGA(FAM-dT)A(THF)(BHQ1-dT)GTGTGGTTTTTTGCG(C3-SPACER)-3'
[0118] The genomic DNA of Klebsiella pneumoniae expressing OXA was used as a positive template, and PCR water was used as a negative control to perform ERA isothermal amplification to detect the detection limit of ERA. In this embodiment, DNA was extracted by thermal lysis. The thermal lysis method was to culture Klebsiella pneumoniae for 5 hours (the harvested cells were approximately equivalent to 10 8 CFU / mL), resuspend 15 μL of Klebsiella pneumoniae cells in 150 μL of extraction buffer, vortex briefly, and then incubate at 95°C for 5 minutes. Take the buffer to dilute the pure genomic DNA of Klebsiella pneumoniae 10 times continuously to obtain a DNA sample with a concentration range of 0.01-10 ng / μL. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1. Parallel experiments are performed with templates of different concentrations, and the fluorescence results are detected.
[0119] The results show that the OXP gene detection method of the present invention has an extremely low detection concentration of 0.01 ng / μL (i.e. 2.2017 copies / μL). Figure 2 .
[0120] Example 3. OXA gene detection in human stool samples
[0121] A 1 g stool sample was collected using a sterile spatula, thawed on ice, and added to 10 ml of ice-cold phosphate-buffered saline (PBS). 900 μL of the stool suspension was transferred to a new Eppendorf tube and inoculated with 100 μL of an overnight culture of an OXA-producing Klebsiella pneumoniae resistant strain to a level of 10 8CFU / 1.0g feces. Take 15μL of the suspension and resuspend it in 150μL of extraction buffer E, vortex gently, and boil at 95℃ for 5 minutes to release DNA. Perform 10-fold gradient dilution of the obtained sample to obtain 10 8 ~10 5 CFU / 1.0g corresponding to the DNA sample. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1, and the primer pair and probe sequence are as described in Example 2. Detect the fluorescence results.
[0122] The results showed that the detection method of the present invention is effective for human fecal samples (10 5 CFU / 1.0g, corresponding to 12.5 CFU Klebsiella pneumoniae) is also effective, see Figure 3 .
[0123] Example 4. Optimal primer pairs and probe specificity for carbapenemase OXA gene
[0124] The optimal primer pair and probe sequence as described in Example 2 were selected, and genomic DNA samples containing different subtypes of carbapenemase (blaNDM, blaVIM, blaOXA, blaIMP, blaKPC) at a concentration of 20 ng were used to evaluate the specificity of the primer pair and probe combination for detecting the OXA gene. The reaction system is as described in Example 1. ddH2O was used for negative control to ensure that amplification would not occur in the absence of target DNA. The amplification temperature was 37°C, the reaction was 20 minutes, and the change in fluorescence was detected using a GS8 fluorescence thermostatic amplification instrument, and the fluorescence was read every 30 seconds.
[0125] The results showed that the amplification curve only appeared in OXA-positive DNA samples, and there was no cross-reaction with other carbapenemase subtype genes blaNDM, blaVIM, blaIMP, and blaKPC ( Figure 4 ), indicating that the primer pair and probe for OXA gene screened by the present invention have extremely high specificity.
[0126] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A non-diagnostic and non-therapeutic method for amplifying the OXA gene, characterized in that: The amplification method comprises the steps of: performing amplification in a reaction system, wherein the reaction system contains a specific primer pair for amplifying the OXA gene, and the primer pair comprises: a sequence as shown in SEQ ID NO:3, and a sequence as shown in SEQ ID NO:
5.
2. The method according to claim 1, characterized in that The method further comprises a probe comprising the sequence shown in SEQ ID NO:
6.
3. A non-diagnostic detection method for OXA gene, characterized in that: The method comprises the steps of: (a) amplifying the sample to be tested using the method according to claim 1; and (b) Perform signal detection.
4. The method according to claim 3, characterized in that The method further comprises providing an OXA negative control and / or an OXA positive control.
5. The method according to claim 3, characterized in that The sample to be tested is a human excrement sample.
6. The method according to claim 3, characterized in that The minimum detection concentration of the method is 0.005-0.015 ng / μL.
7. A detection kit for rapid detection of OXA gene, characterized in that: The detection kit comprises: a container, and a primer pair and a probe specific for the OXA gene in the container, Wherein, the primer pair includes the sequence shown as SEQ ID NO:3 and the sequence shown as SEQ ID NO:5; and the probe includes the sequence shown as SEQ ID NO:
6.
8. A use of the detection kit according to claim 7, characterized in that: Used for non-diagnostic and non-therapeutic detection of whether the test sample contains OXA-type carbapenemase-resistant bacteria.
9. The use according to claim 8, characterized in that The kit is also used to evaluate the antibacterial effect of drugs against OXA-type carbapenemase-resistant bacteria.
10. A specific primer pair for amplifying the OXA gene, characterized in that: The primer pair includes the sequence shown as SEQ ID NO:3 and the sequence shown as SEQ ID NO:5.
Citation Information
Patent Citations
Capture probe set, method and kit for detecting pathogenic microorganisms and application
CN112813196A
Primer probe combination for carbapenem-resistant acinetobacter baumannii RPA-LFS detection method and application thereof
CN114703257A
Detection method
US20190352700A1
